293 related articles for article (PubMed ID: 16899108)
1. Interleukin-6 and rheumatic diseases.
Lipsky PE
Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S4. PubMed ID: 16899108
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis.
Davies R; Choy E
Semin Immunol; 2014 Feb; 26(1):97-104. PubMed ID: 24389239
[TBL] [Abstract][Full Text] [Related]
4. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin-6 in pediatric rheumatic diseases.
De Benedetti F
Curr Opin Rheumatol; 2009 Sep; 21(5):533-7. PubMed ID: 19593141
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
9. [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].
Iking-Konert C; Bartz-Bazzanella P; Falagan D; Hofman MW; Schwarting A; Dörner T
Z Rheumatol; 2014 Apr; 73(3):269-76. PubMed ID: 24166363
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
12. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
13. A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment.
Ozaki Y; Tanaka A; Shimamoto K; Amuro H; Kawakami K; Son Y; Ito T; Wada T; Nomura S
Mod Rheumatol; 2011 Jun; 21(3):302-4. PubMed ID: 21104102
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
Alten R; Maleitzke T
Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6: from identification of the cytokine to development of targeted treatments.
Assier E; Boissier MC; Dayer JM
Joint Bone Spine; 2010 Dec; 77(6):532-6. PubMed ID: 20869898
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
Jones SA; Scheller J; Rose-John S
J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215
[TBL] [Abstract][Full Text] [Related]
17. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 blockade in ocular inflammatory diseases.
Mesquida M; Leszczynska A; Llorenç V; Adán A
Clin Exp Immunol; 2014 Jun; 176(3):301-9. PubMed ID: 24528300
[TBL] [Abstract][Full Text] [Related]
20. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
Cavalli G; Dinarello CA
Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
